Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT04510766 Recruiting - Lymphoma Clinical Trials

Tumor Molecular Profiling in Early Phase Clinical Trials

Start date: October 1, 2020
Phase:
Study type: Observational

Prospective, single centre, non-interventional exploratory research project that will be conducted on biological material and health-related personal data collected.

NCT ID: NCT04510636 Recruiting - Refractory Cancer Clinical Trials

Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma

Start date: December 20, 2021
Phase: Phase 2
Study type: Interventional

This is a phase 2 open-label study to test the safety and effectiveness of combining pembrolizumab and bendamustine in patients with relapsed (cancer that has come back or started getting worse) or refractory (cancer that is not responding or has stopped responding to treatment) Hodgkin lymphoma.

NCT ID: NCT04510610 Recruiting - Hodgkin Lymphoma Clinical Trials

Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Start date: September 1, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

This is an open-label, Phase 2/3,multicenter and single-arm clinical trial of Camrelizumab plus decitabine for Anti-PD-1 treatment-naive patients with relapsed or refractory Hodgkin Lymphoma. The primary objective of this study is to evaluate the long-term response duration with Camrelizumab plus decitabine in relapsed or refractory Hodgkin Lymphoma.

NCT ID: NCT04504526 Recruiting - Multiple Myeloma Clinical Trials

Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases

Start date: August 7, 2020
Phase: Early Phase 1
Study type: Interventional

Chemokine receptor CXCR4 is normally expressed on T-lymphocytes, B-lymphocytes, monocytes, macrophages, neutrophils and eosinophils as well as hematopoietic stem and progenitor cells (HSPC) in the bone marrow. 68Ga-Pentixafor PET/CT represents a promising method for the in vivo assessment of the CXCR4 expression status in cancer patients, especially in hematologic malignancies. This prospective study is going to investigate whether metabolic characterization by 68Ga-Pentixafor PET/CT may be superior for diagnosis, risk stratification, and the prognostic evaluation in lymphoproliferative diseases.

NCT ID: NCT04502394 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

Start date: February 23, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)

NCT ID: NCT04500587 Recruiting - Clinical trials for Acute Myeloid Leukemia

Phase 1 First in Human Study of ZN-d5 as a Single Agent

Start date: October 13, 2020
Phase: Phase 1
Study type: Interventional

Phase 1 dose escalation study of ZN-d5 in subjects with relapsed or refractory non-Hodgkin lymphoma (NHL) or acute myeloid leukemia (AML).

NCT ID: NCT04497688 Recruiting - Clinical trials for Non Hodgkin's Lymphoma

Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

The main treatments for non-Hodgkin's lymphoma are surgery, radiotherapy, chemotherapy, and bone marrow transplantation. Neutropenia is the most common and serious complication of most chemotherapy. This study is a multi-center, open-label, single-arm clinical study to evaluate the efficacy and safety of jinyouli in preventing neutropenia in patients with non Hodgkin's lymphoma after chemotherapy.

NCT ID: NCT04496011 Recruiting - Multiple Myeloma Clinical Trials

Effect of the Cycloergometer in Patients Undergoing Hematopoietic Stem Cell Transplantation

Start date: March 2, 2020
Phase: N/A
Study type: Interventional

Physiological changes caused by hematological diseases associated with high dose chemotherapy have a negative impact on patient's functionality, making them more fragile and vulnerable after hematopoietic cell transplantation. Currently, randomized studies have shown that physical exercise can contribute to improve Quality of Life of these patients. In this randomized controlled trial, we will study the effect of using the bicycle ergometer on the physical performance of patients undergoing transplantation of hematopoietic stem cells (HSCT).

NCT ID: NCT04491370 Recruiting - Clinical trials for Mantle Cell Lymphoma

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

Start date: August 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Patients will receive one of two conditioning regimens (BEAM or CBV) before receiving an autologous stem cell transplant (ASCT). If patients achieve either complete, partial, or stable response following ASCT, they will receive an IV dose of Polatuzumab Vedotin once every 21 days until they receive 8 doses. After Polatuzumab Vedotin therapy is completed, patients will be followed every 4 months for about 2 years.

NCT ID: NCT04490590 Recruiting - NK/T-Cell Lymphoma Clinical Trials

A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma

Start date: October 1, 2016
Phase: Phase 4
Study type: Interventional

To observe the safety, tolerability and clinical effects of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma.